Our Experts

Dr. Frank S. Genbauffe, PhD. 

Laboratory Director

Frank has over 20 years of industrial experience in Molecular Biology and Protein Expression. He has been managing Molecular Diagnostics Laboratories for over five years. 

His work experience includes over 8 years at Procter & Gamble Pharmaceuticals, where he was a Senior Scientist on the Structure Based Drug Design Team. In this capacity, Frank was responsible for recombinant protein production for Discovery Research. Prior to this, Frank worked for over 11 years at Seragen, Inc, a Boston-based biotechnology company, producing genetically engineered forms of recombinant diphtheria toxin. Here, Frank served as the Director of New Product Development.

Katherine Reeves, MLS (ASCP) MBA

VP of Operations

Katherine has 30+ years of experience in running and managing clinical laboratories in hospital systems. With a Medical Technologist and business background, Katherine provides leadership and regulatory oversight.

Dr. Sandra L Nelson, PhD. 

Chief Technology Officer

Sandra is currently responsible for the MDL Laboratory Information System (LIS) and related software; this software stores clinical results data and is used to manage many lab processes. She also is the Quality System Manager with responsibility for maintaining MDL’s high quality results. Sandra has expertise in assay development and high throughput automation, with a number of publications in these areas.

Her work experience includes 18 years at Procter & Gamble Pharmaceuticals where she led of team of approximately 20 that performed high throughput screening (HTS) and managed the automated compound repository in her last position. During the 6 years prior to joining MDL, Sandra established and led an automated HTS lab with image analysis capability at the University of Cincinnati (UC). This HTS lab was part of the UC Drug Discovery Center. Sandra is currently a reviewer for 2 scientific journals, has been a member of NIH several reviewing panels, and held a 3 year term as a board member for the Society for Biomolecular Screening.

Ahmer Kodvawala, MS and MBA 

Chief Scientist

Ahmer studied human molecular genetics and inherited disorders for his Masters in Medical Genetics. He has several years of experience in validating molecular diagnostic tests in clinical laboratory settings.

With several years of biomedical research experience coupled with business acumen, Ahmer leads MDL’s effort to identify new technology and implement new tests for clinical diagnosis.
Tim Stephens, BS, Alma Murga, BS and Megan Hale, BSTechnologists

We have competent and skilled technologists who perform clinical testing under CLIA regulations.

Tim and Alma process hundreds of clinical samples every week using the latest technologies to report patient results. All this work is done according to well established and validated SOPs according to CLIA and CAP guidelines.

Renee Perkins & Karianne Martin

Administration 

We have administrative support personnel and insurance billing capabilities, coordinated by our Office Manager, Renee Perkins and Assistant, Karianne Martin. Renee ensures the integrity of our processes by carefully monitoring the administrative aspects, data entry and insurance billing.

Dr. Jeffrey Huth, PhD. MD.

Medical Advisor

Dr Huth is the Founder and Chief Executive Officer of ScopiaRx, LLC. His work has focused on drug safety at both the research and clinical levels for 20 years. He received a BS in Chemistry from Xavier University in 1988, and a PhD in Pharmacology from the University of Michigan in 1993. From 1993-1997 he trained in protein biophysics at the National Institutes of Health in the laboratories of Dr. G. Marius Clore and Dr. Angela Gronenborn. Between 1997 and 2007, Dr. Huth was a senior scientist and group leader in the Advanced Technology Division of Pharmaceutical Discovery at Abbott Laboratories. There he invented ALARM NMR, which is a technology to predict adverse drug effects prior to costly animal and human studies. His work contributed to three drugs that advanced to clinical trials for rheumatology, oncology, and infectious disease indications. In 2011 he completed an MD degree at the University of Cincinnati College of Medicine, and in 2012, an internship in internal medicine at the University of Cincinnati Medical Center. He has authored over 40 publications in journals such as the Journal of the American Chemical Society, Cell, and the Proceedings of the National Academy of Sciences. Dr. Huth is a member of the American Chemical Society, the American Medical Association, Alpha Omega Alpha, and the American College of Physicians.